KNTE Stock Overview
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States.
Kinnate Biopharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$12.70|
|52 Week High||US$26.05|
|52 Week Low||US$7.18|
|1 Month Change||-6.96%|
|3 Month Change||0.71%|
|1 Year Change||-44.97%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-67.46%|
Recent News & Updates
FDA grants fast track nod to Kinnate Biopharma's skin cancer inhibitor
Clinical-stage oncology company Kinnate Biopharma (NASDAQ:KNTE) on Wednesday said it had got a fast track designation from the U.S. FDA for its inhibitor KIN-2787 for the treatment of patients with melanoma, the most serious type of skin cancer. The exact indication for KIN-2787 is for the treatment of patients with BRAF Class II or III alteration-positive and/or NRAS mutation-positive stage IIb to IV malignant melanoma that is metastatic or unresectable. The FDA's Fast Track approval is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. KIN-2787 is being evaluated in an ongoing phase 1 clinical trial in patients with solid tumors harboring BRAF alterations or who have NRAS mutant melanoma, KNTE said in a statement. The fast track nod for KIN-2787 follows an earlier orphan drug designation granted by the FDA for the treatment of stage IIb-IV melanoma. KNTE stock +4.8% to $12.65 after hours.
Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Kinnate Biopharma GAAP EPS of -$0.62 beats by $0.03
Kinnate Biopharma press release (NASDAQ:KNTE): Q2 GAAP EPS of -$0.62 beats by $0.03. As of June 30, 2022, the total of cash and cash equivalents and investments was $279.6 million, exclusive of Kinnjiu’s cash.
|KNTE||US Biotechs||US Market|
Return vs Industry: KNTE underperformed the US Biotechs industry which returned -27.4% over the past year.
Return vs Market: KNTE underperformed the US Market which returned -22.1% over the past year.
|KNTE Average Weekly Movement||12.6%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: KNTE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: KNTE's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California.
Kinnate Biopharma Fundamentals Summary
|KNTE fundamental statistics|
Is KNTE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|KNTE income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.37|
|Net Profit Margin||0.00%|
How did KNTE perform over the long term?See historical performance and comparison
Is KNTE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for KNTE?
Other financial metrics that can be useful for relative valuation.
|What is KNTE's n/a Ratio?|
Price to Book Ratio vs Peers
How does KNTE's PB Ratio compare to its peers?
|KNTE PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
STOK Stoke Therapeutics
TSVT 2seventy bio
JANX Janux Therapeutics
RPTX Repare Therapeutics
KNTE Kinnate Biopharma
Price-To-Book vs Peers: KNTE is expensive based on its Price-To-Book Ratio (2x) compared to the peer average (2x).
Price to Earnings Ratio vs Industry
How does KNTE's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: KNTE is expensive based on its Price-To-Book Ratio (2x) compared to the US Biotechs industry average (1.6x)
Price to Book Ratio vs Fair Ratio
What is KNTE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||2x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate KNTE's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of KNTE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate KNTE's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate KNTE's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Kinnate Biopharma forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KNTE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: KNTE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: KNTE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: KNTE is forecast to have no revenue next year.
High Growth Revenue: KNTE is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if KNTE's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Kinnate Biopharma performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KNTE is currently unprofitable.
Growing Profit Margin: KNTE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: KNTE is unprofitable, and losses have increased over the past 5 years at a rate of 56.5% per year.
Accelerating Growth: Unable to compare KNTE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KNTE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: KNTE has a negative Return on Equity (-33.96%), as it is currently unprofitable.
Discover strong past performing companies
How is Kinnate Biopharma's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: KNTE's short term assets ($267.1M) exceed its short term liabilities ($11.5M).
Long Term Liabilities: KNTE's short term assets ($267.1M) exceed its long term liabilities ($3.7M).
Debt to Equity History and Analysis
Debt Level: KNTE is debt free.
Reducing Debt: KNTE has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KNTE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: KNTE has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 54.6% each year.
Discover healthy companies
What is Kinnate Biopharma current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Kinnate Biopharma Dividend Yield vs Market|
|Company (Kinnate Biopharma)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.6%|
|Industry Average (Biotechs)||2.7%|
|Analyst forecast in 3 Years (Kinnate Biopharma)||0%|
Notable Dividend: Unable to evaluate KNTE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate KNTE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KNTE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KNTE's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as KNTE has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Nima Farzan (46 yo)
Mr. Nima Farzan, M.B.A., serves as President and Chief Executive Officer at Kinnate Biopharma Inc. and as a Member of Board of Directors since March 2020. Mr. Farzan had been the Chief Executive Officer at...
CEO Compensation Analysis
|Nima Farzan's Compensation vs Kinnate Biopharma Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$8m||US$558k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$5m||US$359k|
Compensation vs Market: Nima's total compensation ($USD7.88M) is above average for companies of similar size in the US market ($USD2.92M).
Compensation vs Earnings: Nima's compensation has increased whilst the company is unprofitable.
Experienced Management: KNTE's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Experienced Board: KNTE's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|14 Mar 22||BuyUS$338,850||Richard Williams||Individual||40,000||US$8.64|
|15 Feb 22||BuyUS$1,989,446||OrbiMed Advisors LLC||Company||195,700||US$10.22|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Kinnate Biopharma Inc.'s employee growth, exchange listings and data sources
- Name: Kinnate Biopharma Inc.
- Ticker: KNTE
- Exchange: NasdaqGS
- Founded: 2018
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$560.649m
- Shares outstanding: 44.15m
- Website: https://www.kinnate.com
Number of Employees
- Kinnate Biopharma Inc.
- 103 Montgomery Street
- Suite 150
- San Francisco
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|6KB||MUN (Boerse Muenchen)||Yes||Common Stock||DE||EUR||Dec 2020|
|KNTE||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Dec 2020|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/28 00:00|
|End of Day Share Price||2022/09/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.